Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial

2009141 citationsJournal Articlegreen Open Access

Authors

Nicole Mittmann · St George Hospital

H. Au · Health Sciences Centre

D. Tu · Austin Health

Christopher J. O’Callaghan · Queen's University

Pierre K. Isogai · Juravinski Cancer Centre

Christos S. Karapetis · Flinders Medical Centre

John Zalcberg ·

Abstract

The incremental cost-effectiveness ratio of cetuximab over best supportive care alone in unselected advanced colorectal cancer patients is high and sensitive to drug cost. Incremental cost-effectiveness ratios were lower when the analysis was limited to patients with wild-type KRAS tumors.

Topics & Keywords

Colorectal Cancer Treatments and Studies Gastric Cancer Management and Outcomes Economic and Financial Impacts of Cancer

Publication Details

Published in: JNCI Journal of the National Cancer Institute

Volume 101, Issue 17, pp. 1182-1192

DOI: 10.1093/jnci/djp232

Field-Weighted Citation Impact: 6.79

Command Palette

Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial

Authors

Abstract

Topics & Keywords

Publication Details